Mettler-Toledo International Inc. — Q3 2023 Form 10-Q
Reporting period: Quarter and nine months ended September 30, 2023; unaudited interim results prepared under U.S. GAAP. The company supplies precision instruments and related services for laboratory, industrial, retail, and other applications. Comparisons are with the corresponding 2022 periods.
Key financial results
| Metric | Q3 2023 | Q3 2022 | Nine months 2023 | Nine months 2022 |
|---|---|---|---|---|
| Net sales | $942.5 million | $985.8 million | $2,853.3 million | $2,862.0 million |
| Gross profit | $559.5 million | $584.7 million | $1,689.6 million | $1,675.9 million |
| Gross margin | 59.4% | 59.3% | 59.2% | 58.6% |
| Earnings before taxes | $251.2 million | $275.9 million | $741.2 million | $745.6 million |
| Net earnings | $201.6 million | $220.6 million | $604.0 million | $606.7 million |
| Diluted EPS | $9.21 | $9.76 | $27.37 | $26.58 |
Q3 sales fell 4% in U.S. dollars and 5% in local currencies; nine-month sales were flat in U.S. dollars and up 1% in local currencies. Q3 net earnings declined about 9%, while nine-month net earnings were down less than 1%; diluted EPS rose about 3% for the nine-month period, aided in part by fewer weighted-average shares. Q3 operating pressure included higher interest and restructuring expense. Interest expense was $20.3 million in Q3 and $57.7 million for nine months, versus $14.5 million and $38.6 million, respectively, in 2022.
Cash flow, balance sheet, and capital allocation
- Cash flow: Nine-month operating cash flow was $684.4 million, up from $555.4 million. Capital expenditures were $72.9 million, compared with $89.2 million. Cash used in financing was $610.6 million, including $724.0 million of share repurchases. Cash declined $26.3 million from year-end to $69.7 million.
- Debt and liquidity: Total debt was $2.108 billion, including $179.1 million current and $1.929 billion long-term debt. Cash was $69.7 million; approximately $545.2 million remained available under the credit agreement. Management reported compliance with debt covenants. The filing estimates debt fair value was about $274.7 million below carrying value.
- Working capital and equity: Inventories declined to $376.0 million from $441.7 million at year-end, and receivables declined to $635.0 million from $709.3 million. Shareholders’ equity was negative $105.9 million, versus positive $24.8 million at year-end, reflecting substantial treasury-stock repurchases and other equity movements.
- Repurchases: The company repurchased 526,019 shares for $724.0 million during the first nine months, and had $2.7 billion of authorization remaining at September 30.
Material changes and operating trends
- China was the principal weakness: Chinese Operations’ external sales fell 29% in U.S. dollars in Q3 (25% in local currency); nine-month external sales fell 11%. Segment profit fell 32% in Q3 and 9% for nine months.
- By destination, Q3 sales rose 12% in Europe in U.S. dollars, fell 3% in the Americas, and fell 17% in Asia/Rest of World. Local-currency sales in China declined 25% in Q3.
- Product sales fell 8% in Q3, while service revenue grew 9% in U.S. dollars. Food retailing sales grew strongly—53% in Q3 in U.S. dollars—partly offsetting declines in laboratory and industrial demand.
- Gross margin improved, mainly due to favorable price realization, partly offset by lower volume, higher costs, mix, and currency translation. SG&A declined, reflecting lower variable compensation and cost-saving initiatives; R&D spending increased.
- Segment performance was mixed: Western European and Other segment profits increased, U.S. profit declined modestly in Q3, Swiss profit declined, and Chinese profit contracted sharply.
Outlook, risks, and contingencies
- The filing provides no specific quantified full-year revenue or earnings guidance. Management expects China sales to remain below prior-year levels for the remainder of 2023 and cautions that market conditions may change quickly.
- Management cites increased economic and end-market uncertainty, possible recession in some countries, weaker life-sciences demand, inflation, and geopolitical developments involving Ukraine and the Israeli-Palestinian conflict.
- Foreign exchange is a material exposure. Management estimates a 1% Swiss franc strengthening against the euro could reduce annual pretax earnings by approximately $2.0–$2.3 million; a 1% renminbi weakening against the U.S. dollar could reduce annual pretax earnings by approximately $3.3–$3.6 million.
- Restructuring charges were $7.4 million in Q3 and $19.7 million for nine months, primarily employee-related. The company also incurred $6.4 million of share-repurchase excise tax for nine months under the Inflation Reduction Act.
- The company expects operating cash flows, available credit, local facilities, and cash balances to cover anticipated needs for the foreseeable future. It expects approximately $27.5 million of 2023 contributions to non-U.S. pension plans. Management does not expect existing legal proceedings to have a material adverse effect; no material legal proceedings were reported in Part II.
Important facts for investors to verify
- Whether weak Chinese demand and lower life-sciences activity persist, and how they affect sales, segment profit, and margins.
- Whether improved gross margin and operating cash flow are sustainable as volume, pricing, costs, and working capital change.
- Debt refinancing and interest-rate exposure, especially given higher interest expense, near-term maturities, and variable-rate borrowings.
- The pace and funding of share repurchases relative to cash generation, debt levels, and negative shareholders’ equity.
- Currency movements, geopolitical and inflation risks, and the timing and impact of restructuring and pension contributions.